§ 520.2087 Roxarsone soluble powder.

(a) Specifications. Each ounce (avoirdupois) of soluble powder contains 21.7 grams of roxarsone (monosodium 3-nitro-4-hydroxyphenylarsonate).

(b) Sponsor. See No. 046573 in § 510.600(c) of this chapter.

(c) Related tolerances. See § 556.60 of this chapter.

(d) NAS/NRC status. These conditions of use are NAS/NRC reviewed and found effective. NADA’s for these uses need not include effectiveness data as specified by § 514.111 of this chapter, but may require bioequivalency and safety information.

§ 520.2088 Roxarsone tablets.

(a)(1) Specifications. Each tablet contains 36 milligrams of roxarsone (3-nitro-4-hydroxyphenylarsonic acid).

(b) Sponsor. See No. 046573 in § 510.600(c) of this chapter.

(c) Related tolerances. See § 556.60 of this chapter.

(d) NAS/NRC status. The weight gain, feed efficiency, and pigmentation claims are NAS/NRC reviewed and found effective. NADA’s for these uses need not include effectiveness data as specified by § 514.111 of this chapter, but may require bioequivalency and safety information.

§ 520.2089 Roxarsone drenches.

(a) Specifications. Each packet contains 0.5 grams of roxarsone (3-nitro-4-hydroxyphenylarsonic acid).

(b) Sponsor. See No. 046573 in § 510.600(c) of this chapter.

(c) Related tolerances. See § 556.60 of this chapter.

§ 520.2090 Roxarsone injectable solution.

(a) Specifications. Each milliliter of injectable solution contains 4.14 milligrams of roxarsone (3-nitro-4-hydroxyphenylarsonic acid).

(b) Sponsor. See No. 046573 in § 510.600(c) of this chapter.

(c) Related tolerances. See § 556.60 of this chapter.

§ 520.2091 Roxarsone faecal powder.

(a) Specifications. Each packet contains 0.002 percent roxarsone (0.5 grams).

(b) Sponsor. See No. 046573 in § 510.600(c) of this chapter.

(c) Related tolerances. See § 556.60 of this chapter.

§ 520.2092 Roxarsone treatment for(c) Lice. Consult veterinarian before using in severely debilitated animals. The drug should be used immediately after the package is opened.

(iv) Warning: Do not treat within 24 hours of slaughter.

(3) Horses and colts:

(i) For the removal and control of infections from the following mature parasites: Large strongyles (Strongylus vulgaris, Strongylus edentatus, Strongylus equinus), small strongyles (Trichonema spp., Triodontophorus), pinworms (Oxyuris), and large roundworms (Parascaris).

(ii) It is administered as a single dose at 12.5 milligrams of pyrantel tartrate per 2.2 pounds of body weight mixed with the usual grain ration.

(iii) It is recommended that severely debilitated animals not be treated with this drug.

(iv) Warning: Do not use in horses or colts intended for food.

[40 FR 13838, Mar. 27, 1975, as amended at 59 FR 28769, June 3, 1994; 69 FR 41427, July 9, 2004]
Food and Drug Administration, HHS

§ 520.2089 Roxarsone liquid.

(a) Specifications. Each teaspoon (5 milliliters) of solution contains 72 milligrams of roxarsone (3-nitro-4-hydroxyphenylarsonic acid).

(b) Sponsor. See No. 046573 in §510.600(c) of this chapter.

(c) Related tolerances. See §556.60 of this chapter.

(d) Conditions of use in growing chickens and growing turkeys—(1) Amount. 1 teaspoon (5 milliliters) to each gallon of drinking water (0.002 percent roxarsone).

(2) Indications for use. For improved rate of weight gain, improved feed efficiency, and improved pigmentation.

(3) Limitations. Administer continuously throughout growing period. Do not administer to chickens producing eggs for human consumption. Withdraw 5 days before slaughter. Use as sole source of organic arsenic. Overdosage or the lack of water intake may result in weakness or paralysis of legs.

§ 520.2098 Selegiline hydrochloride tablets.

(a) Specifications. Each tablet contains either 2, 5, 10, 15, or 30 milligrams of selegiline hydrochloride.

(b) Sponsor. See No. 000069 in §510.600(c) of this chapter.

(c) [Reserved]

(d) Conditions of use—Dogs—(1) Dosage. 1 milligram per kilogram (0.45 milligram per pound) of body weight.

(i) Indications for use. For control of clinical signs associated with uncomplicated pituitary-dependent hyperadrenocorticism in dogs.

(ii) Limitations. Administer orally once daily. If no improvement in clinical signs or physical examination findings after 2 months of therapy, increase dose to a maximum of 2 milligrams per kilogram once daily. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 520.2098 Roxarsone liquid.

(a) Specifications. Each tablet contains 400 milligrams of roxarsone (3-nitro-4-hydroxyphenylarsonic acid).

(b) Sponsor. See No. 046573 in §510.600(c) of this chapter.

(c) Related tolerances. See §556.60 of this chapter.

(d) Conditions of use—Swine—(a) Amount. 1 tablet (400 milligrams) per gallon of drinking water for no more than 6 days, or 1 tablet (400 milligrams) per 2 fluid ounces of warm water per 50 pounds of body weight as a drench once daily for 1 to 2 days.

(b) Indications for use. As an aid in the treatment of swine dysentery (hemorrhagic enteritis or bloody scours).

(c) Limitations. Treatment may be repeated after 5 days off medication. If no improvement is observed, consult a veterinarian. Treated animals must consume enough medicated water to provide a therapeutic dose. Withdraw 5 days before slaughter. Use as sole source of organic arsenic.

§ 520.2089 Roxarsone liquid.

(a) Specifications. Each teaspoon (5 milliliters) of solution contains 72 milligrams of roxarsone (3-nitro-4-hydroxyphenylarsonic acid).

(b) Sponsor. See No. 046573 in §510.600(c) of this chapter.

(c) Related tolerances. See §556.60 of this chapter.

(d) Conditions of use in growing chickens and growing turkeys—(1) Amount. 1 teaspoon (5 milliliters) to each gallon of drinking water (0.002 percent roxarsone).

(2) Indications for use. For improved rate of weight gain, improved feed efficiency, and improved pigmentation.

(3) Limitations. Administer continuously throughout growing period. Do not administer to chickens producing eggs for human consumption. Withdraw 5 days before slaughter. Use as sole source of organic arsenic. Overdosage or the lack of water intake may result in weakness or paralysis of legs.

§ 520.2098 Selegiline hydrochloride tablets.

(a) Specifications. Each tablet contains either 2, 5, 10, 15, or 30 milligrams of selegiline hydrochloride.

(b) Sponsor. See No. 000069 in §510.600(c) of this chapter.

(c) [Reserved]

(d) Conditions of use—Dogs—(1) Dosage. 1 milligram per kilogram (0.45 milligram per pound) of body weight.

(i) Indications for use. For control of clinical signs associated with uncomplicated pituitary-dependent hyperadrenocorticism in dogs.

(ii) Limitations. Administer orally once daily. If no improvement in clinical signs or physical examination findings after 2 months of therapy, increase dose to a maximum of 2 milligrams per kilogram once daily. Federal law restricts this drug to use by or on the order of a licensed veterinarian.